Respiratory Syncytial Virus News and Research

RSS

Kineta's next generation antiviral program receives $2.8 million NIH SBIR grant

Kineta, Inc. announced today its next generation antiviral program has received a 2.8 million dollar grant from the National Institute of Allergy and Infectious Disease, a part of the National Institutes of Health (NIH). Awarded under the Small Business Innovation Research (SBIR) program, the prestigious phase two grant will provide on-going support for Kineta's work on a new class of antiviral drugs targeting an array of global, deadly viruses.

12 Aug 2011

Study finds very low rates of pertussis in children with cough

Contrary to some recent studies, only a low percentage of children treated for respiratory illness with cough have unsuspected pertussis, reports a study in the August issue of The Pediatric Infectious Disease Journal. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.

10 Aug 2011

NIH, NanoBio sign licensing agreement to develop vaccine against RSV infections

NanoBio Corporation today announced a licensing agreement with the National Institutes of Health (NIH) that represents a significant step forward in developing the first vaccine to protect against respiratory syncytial virus (RSV) infections.

4 Aug 2011

Alnylam second quarter revenue decreases to $20.6 million

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today reported its consolidated financial results for the second quarter 2011, and company highlights.

From Precision NanoSystems Inc. 2 Aug 2011

Serious RSV infections may occur in previously healthy infants and children

For most parents, respiratory syncytial virus (RSV) isn't a familiar term. But it's a common cause of serious respiratory infections with a major impact on the health of infants and young children worldwide, according to a special CDC Review Article in the June issue of The Pediatric Infectious Disease Journal. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.

16 Jun 2011

Novavax first quarter net loss decreases to $7.5 million

Novavax, Inc. today announced its financial results for the first quarter ended March 31, 2011.

9 May 2011

Quest Diagnostics' Simplexa C. difficile test is now available in Europe

Quest Diagnostics Incorporated, the world's leading provider of diagnostic testing, information and services, today announced the availability in Europe of the Simplexa C. difficile Universal Direct test on the 3M Integrated Cycler.

From Quest Diagnostics 6 May 2011

FDA clears ITI's FilmArray RP assay for respiratory virus detection

Idaho Technology, Inc. announced today that the U.S. Food and Drug Administration has issued a 510(k) clearance for the FilmArray instrument and the FilmArray Respiratory Panel.

3 May 2011

MedImmune abstracts on influenza and RSV to be presented at PAS meeting

MedImmune announced today it will present 11 abstracts at the Pediatric Academic Societies Meeting at the Colorado Convention Center in Denver, CO, April 30 - May 3, 2011.

2 May 2011

Gilead, MicroDose enter collaboration for inhalable small molecule antiviral fusion inhibitor MDT-637

Gilead Sciences, Inc. and MicroDose Therapeutx, Inc. today announced that the companies have entered into an exclusive worldwide license and collaboration agreement for the development and commercialization of MDT-637, MicroDose's inhalable small molecule antiviral fusion inhibitor for the treatment of respiratory syncytial virus (RSV).

20 Apr 2011

Quest Diagnostics Simplexa molecular test receives bronze award for best new product

Quest Diagnostics Incorporated, the world's leading provider of diagnostic testing, information and services, today announced that the Simplexa™ molecular test on the 3M™ Integrated Cycler was honored with a bronze award for best new science and medical diagnostic product during the 2011 Edison Awards gala ceremony last night in New York City.

From Quest Diagnostics 7 Apr 2011

New discovery in childhood respiratory disease

Researchers have identified a critical part of the process by which one of the world's most common and dangerous early childhood infections, respiratory syncytial virus, causes disease.

8 Mar 2011

February is again peak time for influenza across the nation

If you thought the regular seasonal flu has been late making its annual appearance, you might be surprised to learn that based on recent history, it's right on time.

15 Feb 2011

Collaborative study may lead to improved influenza vaccine and vaccines for other respiratory virus infections

A collaborative project between researchers at the Trudeau Institute and their colleagues at St. Jude Children's Research Hospital in Memphis, Tenn., offers new insights that may lead to an improved strategy to protect against the influenza virus and other viruses that infect the respiratory tract.

19 Jan 2011

Immunization with VLP vaccine results in functional, protective immune responses against RSV

Novavax, and scientists at the University of Massachusetts Medical School, led by Dr. Trudy Morrison, published in the January 2011 issue of The Journal of Virology, a report indicating that a novel virus-like particle vaccine candidate against respiratory syncytial virus (RSV) protects mice from a live virus challenge.

23 Dec 2010

FDA clears Novavax's Phase I clinical trial to evaluate new RSV vaccine candidate

Novavax, Inc. announced today that the company's Phase I clinical trial to evaluate a new vaccine candidate to prevent respiratory syncytial virus (RSV) infection has been cleared by the U.S. Food and Drug Administration (FDA) and is no longer on clinical hold. In November, the company reported that it had received a question from the FDA regarding chemistry, manufacturing and controls (CMC) that has now been resolved.

16 Dec 2010

Encouraging GenVec RSV vaccine program data presented at International Respiratory Syncytial Virus Symposium

GenVec, Inc. announced today that data were presented on GenVec's respiratory syncytial virus (RSV) vaccine program at the International Respiratory Syncytial Virus Symposium, which took place in Rotterdam, Netherlands on December 2-5, 2010. The presentation was given by Barney S. Graham, MD, PhD, Chief, Viral Pathogenesis Laboratory and Chief, Clinical Trials Core, at the Vaccine Research Center (VRC) of the National Institutes of Health (NIH).

7 Dec 2010

Alexion Pharmaceuticals reports interim results from phase 1 trial on samalizumab antibody

Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced the presentation of interim results from the first Phase I/II trial of samalizumab, the company's investigational, first-in-class humanized monoclonal antibody.

6 Dec 2010

Bill & Melinda Gates Foundation awards $6M grant to NanoBio to develop intranasal vaccine for RSV

NanoBio Corporation announced today that it has received a $6M grant from the Bill & Melinda Gates Foundation to support the development of a safe and effective intranasal vaccine for Respiratory Syncytial Virus (RSV).

1 Dec 2010

World Lung Foundation report highlights prevalence of acute respiratory infections worldwide

Acute respiratory infections (ARIs) - such as influenza, pneumonia and respiratory syncytial virus (RSV) - cause 4.25 million deaths each year often among young children in developing countries, according to the Acute Respiratory Infections Atlas, which was released on Tuesday by the World Lung Foundation, Reuters reports (11/9).

10 Nov 2010